$RIGL The two companies will jointly develop R552 and Lilly will be responsible for its global commercialization. Rigel has the right to co-commercialize R552 in the US. Rigel is also entitled to royalty payments varying from mid single digits to high teens dependent on its investment in clinical development. Since it is jointly developed if Eli Lilly says they did 95% of the work and Rigel 5% they are not getting anywhere near an additional 800 million and that is why this stock did not run because there are no guarantees in this deal except 125 millon.
1 Like